AIM ImmunoTech Inc

ASE:AIM   4:00:00 PM EDT
0.44
0.00 (-0.68%)
Products

Aim Immunotech Inc’S Drug Ampligen Awarded FDA’S Orphan Drug Designation Status For The Treatment Of Pancreatic Cancer

Published: 12/21/2020 11:56 GMT
AIM ImmunoTech Inc (AIM) - Aim Immunotech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer.